Phase I-II Study of Paclitaxel, Cisplatin, and Gemcitabine in Advanced Transitional-Cell Carcinoma of the Urothelium
Joaquim Bellmunt(Dana-Farber Cancer Institute), José Baselga(Novartis (Switzerland)), Eduardo Díaz‐Rubio(Hospital Clínico San Carlos), José A. Martinez‐Climent(Marqués de Valdecilla University Hospital), Miguel Nogué(Marqués de Valdecilla University Hospital), R. Bastús(Marqués de Valdecilla University Hospital), Joan Albanell(Universitat Pompeu Fabra), J.L. González-Larriba(Hospital Clínico San Carlos), A. Sáenz(Marqués de Valdecilla University Hospital), M. López-Brea(Marqués de Valdecilla University Hospital), E. Batiste-Alentorn(Marqués de Valdecilla University Hospital), Enrique Gallardo(Marqués de Valdecilla University Hospital), Juan J. de la Cruz(Centro de Investigación Biomédica en Red), Luis Paz‐Ares(Universidad Complutense de Madrid), Vicente Guillém(Marqués de Valdecilla University Hospital), J.M. Banús(Marqués de Valdecilla University Hospital), Albert Font(Marqués de Valdecilla University Hospital), Joan Carles(Vall d'Hebron Hospital Universitari), H. Cortés-Funes(Centre Hospitalier René-Dubos)
Cited by 191
Related Papers
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer
|Journal of Clinical Oncology|2000|3.8k
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k